COMMUNIQUÉS West-GlobeNewswire

Genfit: GENFIT ANNONCE LA SUSPENSION DU COURS DE SES ACTIONS ET DE SES OCEANES SUR EURONEXT PARIS ET EURONEXT ACCESS
27/03/2019
CE COMMUNIQUÉ N’EST PAS DESTINÉ A ÊTRE PUBLIÉ, DISTRIBUÉ OU DIFFUSÉ, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS D’AMÉRIQUE NI À DES RESSORTISSANTS AMÉRICAINS (« U.S. PERSONS »), POUR LEUR BÉNÉFICE OU POUR LEUR COMPTE [...]
Aino Health AB (publ): Aino Health and Veritas Pension Insurance will launch Work Ability Support Service Center
27/03/2019
27 th of March, 2019 Aino Health together with Veritas Pension Insurance co-created and will launch a unique work ability support service for Veritas' customers. The service will be operational in Q2 2019. In the first [...]
Genfit: GENFIT Announces Pricing of Global Offering and Approval to List on Nasdaq Global Select Market
27/03/2019
FOR IMMEDIATE RELEASE GENFIT Announces Pricing of Global Offering and Approval to List on Nasdaq Global Select Market Lille (France), Cambridge (Massachusetts, United States), March 27, 2019 – GENFIT SA (Euronext: GNFT [...]
Genfit: GENFIT annonce le succès de son introduction en bourse sur le Nasdaq dans le cadre d’une offre globale d’American Depositary Shares aux États-Unis et d’un placement privé d’actions
27/03/2019
CE COMMUNIQUÉ N’EST PAS DESTINÉ A ÊTRE PUBLIÉ, DISTRIBUÉ OU DIFFUSÉ, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS D’AMÉRIQUE NI À DES RESSORTISSANTS AMÉRICAINS (« U.S. PERSONS »), POUR LEUR BÉNÉFICE OU POUR LEUR COMPTE [...]
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
27/03/2019
Mayzent ® (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years[1] Up to 80% of patients with relapsing remitting MS [...]
MyoKardia Announces Pricing of Public Offering of Common Stock
26/03/2019
SOUTH SAN FRANCISCO, Calif., March 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious [...]
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2018 Financial and Operating Results
26/03/2019
CHARLESTON, S.C., March 26, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today reported its financial and operating results for the fourth quarter and year ended December 31, 2018. All [...]
Harvard Bioscience To Showcase Products at Experimental Biology 2019
26/03/2019
All Three Commercial Units to Be Represented HOLLISTON, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), a global developer, manufacturer and marketer of a broad range of solutions to [...]
Lutronic Vision Engages World Renowned Retina Expert for R:GEN™ Pilot AMD Clinical Study
26/03/2019
-Key opinion leader Professor Robyn Guymer expected to serve as study’s principal investigator- BILLERICA, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- Lutronic Vision (“Lutronic” or “the Company”), a wholly-owned [...]
Precision Therapeutics Inc. Announces Proposed Public Offering of Securities
26/03/2019
MINNEAPOLIS, March 26, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced a proposed public offering of its common stock and warrants to purchase common [...]
ImmuCell Corporation Announces Commencement of Public Offering of Common Stock
26/03/2019
PORTLAND, Maine, March 26, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and [...]
Selecta Biosciences Announces New Employment Inducement Grant
26/03/2019
WATERTOWN, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating [...]
PhaseBio Reports Fourth Quarter and Full-Year 2018 Financial and Business Results
26/03/2019
Results from Phase 1 clinical trial of PB2452 published in the New England Journal of Medicine and presented at the American College of Cardiology’s Annual Scientific Session Initiated Phase 2b trial of PB1046 for the [...]
ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership
26/03/2019
LEIDEN, Netherlands and CAMBRIDGE, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the [...]
Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemotherapy
26/03/2019
CAMBRIDGE, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food [...]
Guerbet: 2018 annual results
26/03/2019
2018 annual results Growth and EBITDA in line with announced targets Reported revenue: €789.6 million Revenue at constant exchange rates: €825.7 million; +2.3%, in line with the guidance given at Capital Markets Day in [...]
GUERBET: Résultats annuels 2018
26/03/2019
Résultats annuels 2018 Croissance et EBITDA conformes aux objectifs annoncés Chiffre d’affaires publié : 789,6 M€ Chiffre d’affaires à taux de change constant : 825,7 M€ ; +2,3%, en ligne avec la guidance donnée lors du [...]
I-PEN® Osmolarity System Now Available in Brazil Through Partnership with DryCom
26/03/2019
MONTREAL, March 26, 2019 (GLOBE NEWSWIRE) -- I-MED Pharma, Inc., a Canadian company specializing in dry eye diagnosis and management, announced today the signing of an exclusive agreement with DryCom - Dry Eye Solutions [...]
OSE Immunotherapeutics Announces New Research Collaboration with Léon Bérard Cancer Center to Use Artificial Intelligence Technologies to Identify Novel Immuno-Oncology Targets
26/03/2019
Findings from the collaboration will provide relevant information, especially for the development of novel bispecific antibodies (BiCKI® platform) NANTES, France, March 26, 2019 (GLOBE NEWSWIRE) -- OSE [...]

Pages